Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Go back to Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Caladrius Biosciences, Inc. (LSTA) Reports Q4 Loss of $0.76/sh

March 30, 2023 4:56 PM EDT

Caladrius Biosciences, Inc. (NASDAQ: LSTA) reported Q4 EPS of ($0.76), versus ($1.70) reported last year.

For earnings history and earnings-related data on Caladrius Biosciences, Inc. (LSTA) click here.

... More